---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-220557"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:44:09.081760+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Halozyme proposes $500M convertible notes due 2028, plans $200M share repurchase and debt repayment

## Summary
- $500M aggregate principal of convertible senior notes due 2028; initial purchasers have option for additional $75M.
- Proceeds uses: up to $200M share repurchases (increase of $100M vs prior 2022 plan), exchange of existing 1.25% convertibles, and repayment of $250M term loan due 2026.
- Capped call transactions will be entered to reduce potential dilution upon conversion of the notes.
- Interest rate and conversion rate determined at pricing; conversions settled in cash plus stock if applicable.

## SEC filing metadata
- accession: 0001193125-22-220557
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312522220557/0001193125-22-220557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312522220557/d295619d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-220557
- JSON: https://secwatch.observer/filing/0001193125-22-220557.json
- Plain text: https://secwatch.observer/filing/0001193125-22-220557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.